At ViCentra, we like to keep things simple. We believe that if products are easy to use, look beautiful and deliver unbeatable results, they’ll be satisfying to use and more likely to help people achieve everything they want to.
It all started back in 2013, when two engineers with professional backgrounds in insulin pumping and close personal links to people with diabetes set about trying to shake things up. Our engineers thought the existing pumping options were a little rigid, plenty bland, and they saw what other companies seemed not to: the fact that each person with diabetes is different, with different tastes and needs. So, they got to work designing and making Kaleido: a simple, user friendly insulin pump.
Since then, proving that diabetes is no untamable beast has stayed at ViCentra’s centre. Our mission was set: to shrink diabetes back down to size and minimise the impact it has on the lives of people who live with it every day. The Kaleido system consists of two pumps and one handset, and thanks to a one-of-a-kind pumping mechanism, our pumps are small – 50 x 35 x 12.5mm, to be precise. We have pump and body patches and two different lengths of tubing to allow our users to choose how to wear it and our pumps and handset come in 10 rainbow-spanning colour combinations.
We want to make sure people with diabetes have a voice. And we feel it’s so important that we listen. That’s why, alongside making Kaleido, we’ve made strong links within the diabetes community. As well as checking in often with our current and potential users, we work with other organizations, like our friends at Diabeloop and JDRF, to help develop ideas and continue to make things better for those rocking Type 1.
We know that creating brilliant products doesn’t end in the lab though – we also believe in the power of great customer experiences. So, we’re creating healthcare products with this philosophy firmly in mind. At ViCentra, we don’t design for patients – we design for people.
Our Team
Tom Arnold
Tom Arnold brings nearly 25 years of leadership in the MedTech industry to ViCentra, with deep expertise in commercialization, strategy, and product launches. He has held executive roles at Medtronic, PROCEPT BioRobotics, Sorin Group, and Boston Scientific, driving growth and market expansion across multiple healthcare sectors.
Tom’s connection to diabetes is personal—his youngest daughter was diagnosed with type 1 diabetes at just 11 months old. This firsthand experience fuels his passion for delivering innovative, intuitive solutions that simplify life with diabetes.
As CEO of ViCentra, Tom is leading the company’s growth and international expansion, ensuring more people have access to Kaleido, a flexible and personalized insulin pump therapy designed to let users live life on their own terms.
Ian Wells
CFO
Ian joined ViCentra in June 2026, bringing 19 years of global finance leadership across life sciences and MedTech. As a CFO, Ian has led a multibillion-dollar global MedTech driving revenue growth and margin expansion, with a keen focus on ESG, purpose, and impact.
At ViCentra, Ian is focused on building the financial infrastructure to support the company’s next phase of growth, bringing the Kaleido system to more people living with diabetes. Outside work, Ian is focused on healthspan, longevity, and his young family.
Tim Oakes
CTO and Co-founder
As co-founder, we wouldn’t be where we are today without Tim. Tim is an award-winning design engineer with over seven years of experience in the medical device field, mostly related to drug delivery systems. Having grown up with a father with Type 1 diabetes, Tim has first-hand knowledge of the challenges of trying to fit medical devices into daily life. Tim’s ultimate goal for Kaleido? To keep things simple so Kaleido can make life easier for people with diabetes.
Ruchika Bhatnagar
VP People
Ruchika Bhatnagar brings 20+ years of global People leadership experience across fast-scaling, complex, and regulated environments. She has held senior roles at Crocs, AB InBev, Swisscom, Shell, Tamoil, and NATO, helping organizations scale while strengthening leadership, culture, and talent foundations.
Known for combining strategic insight with hands-on execution, Ruchika excels at simplifying complexity, building trust, and guiding teams through transformation with clarity and empathy. Her expertise spans workforce strategy, organizational effectiveness, leadership development, and inclusive culture building.
Based in the Netherlands, she partners with leaders across ViCentra to strengthen its People foundation and support growth, fostering environments where people and performance thrive together.
Reman McDonagh
VP Global Marketing
Reman brings more than 20 years of diabetes expertise across Roche, Medtronic, Cellnovo, and Insulet. A seasoned medical device marketing leader in upstream and downstream marketing across international markets. Reman combines end-to-end commercial experience with a strong track record in brand strategic planning, Go To Market execution and scaling demand responsibly while maintaining excellence in customer experience. She is known for building high-performing teams and enabling effective execution to accelerate adoption.
Karen Baxter
SVP Sales
Karen Baxter is an accomplished healthcare leader with nearly 20 years of experience across European diabetes markets. She joins from Dexcom, where she spent over nine years and most recently served as Vice President and General Manager for Northern Europe and selected international markets. Previously, she has held senior executive roles at Innovex, Pfizer Consumer Healthcare, and Johnson & Johnson. Karen is deeply committed to expanding access to healthcare solutions for broad populations.
Pieter Van Hoof
SVP of Operations
Pieter joined ViCentra in July 2021 and is responsible for ViCentra’s Operations. Since the start of his career, Pieter has predominantly developed his Operations expertise working in the pharmaceutical, chemical and medical device industry assuming various increasingly more responsible roles in manufacturing, supply Chain and general management always with a focus on developing an effective and efficient Operations organization. Outside work he enjoys spending time with his family and getting together with friends for a good ride on the gravel bike and supporting his local football team.
Jay Little
VP Strategy & Business Development
Jay Little joined ViCentra in October 2025 as Vice President of Strategy & Business Development, bringing nearly 25 years of leadership across the medical device and pharmaceutical sectors. Jay spent the previous 18 years at Medtronic in the US, where he held pivotal roles in sales and market access leadership. At ViCentra, he oversees corporate strategy, business development, and strategic partnerships. A specialist in market access and commercial execution, Jay is focused on driving long-term scalability and commercial readiness. He is deeply committed to expanding access to transformative diabetes technologies and building the global alliances necessary to bring the Kaleido experience to the diabetes community.
Kees den Besten
Kees den Besten joined ViCentra in 2024 as VP of Quality Assurance and Regulatory Affairs (QARA). With over 30 years of experience in the medical device industry, Kees has held leadership roles at Medtronic, Cordis (J&J), Baxter, HOYA Surgical Optics and most recently, DORC International. His career started at the regulatory body KEMA and from there he moved to industry, where he’s led global QARA operations and driven quality management initiatives. Kees is passionate about ensuring product excellence and user safety, and at ViCentra, he’s focused on building a culture of continuous improvement in quality and compliance.
Our Board
Jan Keltjens
Chairman of the Board of Directors
Jan joined our Board as Chairman in 2017. He also serves as Chairman of the Board of Directors of JenaValve Technologies Inc. Prior to this he served as Chairman of Nightbalance, Board member and CEO of Sapiens Steering Brain Stimulation, Chairman and CEO of Endosense SA, Executive Chairman of Surpass Medical, President and CEO of AngioDynamics Inc [NASDAQ:ANGO] and CEO of CryoCath Technologies Inc. [TSX:CYT]. In addition, he is associated with a number of venture capital funds. These include NextGen Ventures and Brightlands Venture Partner Funds.
Jan also served as Worldwide General Manager at Cordis Neurovascular, a Johnson & Johnson company, as well as various global and regional leadership roles in Operations, R&D and Marketing at Cordis, Johnson & Johnson. Prior to this, Jan led R&D departments at Unilever.
Tom Arnold
Executive Board Member
Tom Arnold brings nearly 25 years of leadership in the MedTech industry to ViCentra, with deep expertise in commercialization, strategy, and product launches. He has held executive roles at Medtronic, PROCEPT BioRobotics, Sorin Group, and Boston Scientific, driving growth and market expansion across multiple healthcare sectors.
Tom’s connection to diabetes is personal—his youngest daughter was diagnosed with type 1 diabetes at just 11 months old. This firsthand experience fuels his passion for delivering innovative, intuitive solutions that simplify life with diabetes.
As CEO of ViCentra, Tom is leading the company’s growth and international expansion, ensuring more people have access to Kaleido, a flexible and personalized insulin pump therapy designed to let users live life on their own terms.
Thomas A. West
Tom West is an Independent Board Member at ViCentra. He most recently served as President, Chief Executive Officer and Director of Nalu Medical, a venture-backed neurostimulation company in the pain space, where he led the company to a $600 million acquisition by Boston Scientific in early 2026. Previously, he was President, Chief Executive Officer and Director of Intersect ENT (NASDAQ XENT), leading it to a $1.1 billion acquisition by Medtronic in 2022. Earlier in his career, Tom spent 23 years at Johnson & Johnson, including roles as Worldwide Vice President of Strategy and Business Development for J&J’s diabetes companies and Division President of LifeScan in North America and EMEA. He currently serves as an Independent Director of SI-BONE (NASDAQ: SIBN), a specialty orthopedics company, and Cyted, a venture-backed cancer detection company. He previously served on the Boards of Orthofix (NASDAQ OFIX) and Inogen (NASDAQ INGN).
Caaj Greebe
Coming soon
Fokke de Vries
Fokke de Vries has 20 years of experience with private equity funds and private equity-owned companies. He has been involved with Partners in Equity since 2025 and joined the board of ViCentra in July 2025. Next to ViCentra, Fokke currently represents PiE at a number of other portfolio companies within the PiE portfolio. Prior to joining Partners in Equity, Fokke worked as an investment manager involved with private equity investments in the medical device industry as well as other industries.
Anne Portwich
Anne Portwich is a Partner in the EQT Life Sciences team. Anne worked for LSP from 2001 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences.
Prior to joining LSP, Anne worked as a Scientist and Project Leader at OctoPlus in Leiden, the Netherlands. Anne holds an MSc in Biochemistry from the University of Hanover and a PhD from the Max-Planck Institute of Marine Microbiology in Bremen.
Theo Sonnenberg
Theo Sonnenberg, Independent Board Member at ViCentra, is the former CEO and shareholder of D.O.R.C. Holding, with over 25 years of international experience in health care and medtech, including extensive work in private equity and venture capital. He transformed D.O.R.C. from a small instrument company into a global eye-surgery technology leader, growing sales to over €125 million and guiding two successful PE acquisitions. After D.O.R.C.’s acquisition by Montagu, Theo remained Non-Executive Director until its sale to Eurazeo. He is currently LP in various funds and serves as Non-Executive Director and Chairman for several PE- and VC-owned companies. Having worked for Fortune top 500 companies, European and USA based private equity firms, and family-owned businesses, Theo brings broad experience across company types.
Our advisors
Dr. G. E. M. G. Storms
Dr. G. E. M. G. (Fred) Storms is one of the Netherlands’ leading authorities on the treatment of diabetes mellitus. Medical Director of the Diabetes Care team at St. Antonius Hospital, Utrecht until his retirement in 2016, Dr. Storms holds a special interest in the medical and technical advancements being made to improve diabetes treatment, and, as such, his work has long focussed on encouraging and supporting such advancements. He has participated in multiple international studies, including AT.LANTUS, PROactive, ONTARGET and EMPA-REG, and contributed to several trials of leading insulin pump therapies.
Our investors
INKEF
EQT Life Science
Health Innovations
Partners in Equity
Invest-NL
